<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p4" style="overflow: hidden; position: relative; background-color: white; width: 1286px; height: 909px;">

<!-- Begin shared CSS values -->
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<!-- End shared CSS values -->


<!-- Begin inline CSS -->
<style type="text/css" >

#t1_4{left:89px;bottom:23px;letter-spacing:-0.46px;word-spacing:0.13px;}
#t2_4{left:352px;bottom:29px;}
#t3_4{left:359px;bottom:23px;letter-spacing:-0.03px;}
#t4_4{left:391px;bottom:29px;}
#t5_4{left:396px;bottom:23px;letter-spacing:-0.27px;word-spacing:-0.21px;}
#t6_4{left:558px;bottom:29px;}
#t7_4{left:565px;bottom:23px;letter-spacing:-0.39px;word-spacing:-0.09px;}
#t8_4{left:335px;bottom:836px;letter-spacing:0.22px;word-spacing:-0.51px;}
#t9_4{left:335px;bottom:806px;letter-spacing:0.38px;word-spacing:-0.68px;}
#ta_4{left:1139px;bottom:25px;letter-spacing:-0.05px;}
#tb_4{left:89px;bottom:755px;letter-spacing:-0.09px;word-spacing:0.08px;}
#tc_4{left:89px;bottom:733px;letter-spacing:-0.12px;word-spacing:0.11px;}
#td_4{left:89px;bottom:710px;letter-spacing:-0.14px;word-spacing:0.11px;}
#te_4{left:89px;bottom:688px;letter-spacing:-0.07px;word-spacing:-1.01px;}
#tf_4{left:89px;bottom:665px;letter-spacing:-0.18px;word-spacing:0.16px;}
#tg_4{left:89px;bottom:642px;letter-spacing:-0.06px;word-spacing:0.04px;}
#th_4{left:89px;bottom:620px;letter-spacing:-0.17px;word-spacing:0.15px;}
#ti_4{left:89px;bottom:597px;letter-spacing:-0.15px;word-spacing:0.12px;}
#tj_4{left:89px;bottom:575px;letter-spacing:-0.15px;word-spacing:0.12px;}
#tk_4{left:600px;bottom:582px;letter-spacing:-0.17px;}
#tl_4{left:89px;bottom:552px;letter-spacing:-0.09px;word-spacing:0.07px;}
#tm_4{left:89px;bottom:529px;letter-spacing:-0.19px;word-spacing:-0.45px;}
#tn_4{left:284px;bottom:537px;letter-spacing:-0.16px;}
#to_4{left:327px;bottom:529px;letter-spacing:-0.07px;word-spacing:-0.75px;}
#tp_4{left:89px;bottom:507px;letter-spacing:-0.09px;word-spacing:-0.46px;}
#tq_4{left:89px;bottom:484px;letter-spacing:-0.13px;word-spacing:0.1px;}
#tr_4{left:89px;bottom:462px;letter-spacing:-0.03px;}
#ts_4{left:334px;bottom:462px;}
#tt_4{left:343px;bottom:462px;letter-spacing:-0.09px;word-spacing:0.06px;}
#tu_4{left:89px;bottom:439px;letter-spacing:-0.11px;word-spacing:0.1px;}
#tv_4{left:89px;bottom:401px;letter-spacing:0.07px;}
#tw_4{left:89px;bottom:372px;letter-spacing:-0.11px;word-spacing:0.08px;}
#tx_4{left:89px;bottom:350px;letter-spacing:-0.16px;word-spacing:-1.09px;}
#ty_4{left:308px;bottom:350px;letter-spacing:-0.1px;word-spacing:-0.28px;}
#tz_4{left:89px;bottom:327px;letter-spacing:-0.12px;word-spacing:0.1px;}
#t10_4{left:89px;bottom:305px;letter-spacing:-0.21px;word-spacing:0.19px;}
#t11_4{left:89px;bottom:282px;letter-spacing:-0.15px;word-spacing:0.12px;}
#t12_4{left:89px;bottom:260px;letter-spacing:-0.16px;word-spacing:-0.67px;}
#t13_4{left:89px;bottom:237px;letter-spacing:-0.06px;word-spacing:-0.98px;}
#t14_4{left:428px;bottom:237px;letter-spacing:-0.13px;word-spacing:0.1px;}
#t15_4{left:563px;bottom:237px;}
#t16_4{left:573px;bottom:237px;letter-spacing:-0.12px;}
#t17_4{left:89px;bottom:214px;letter-spacing:-0.06px;word-spacing:0.04px;}
#t18_4{left:89px;bottom:173px;letter-spacing:0.09px;word-spacing:0.98px;}
#t19_4{left:89px;bottom:145px;letter-spacing:-0.14px;word-spacing:-0.94px;}
#t1a_4{left:89px;bottom:124px;letter-spacing:-0.05px;word-spacing:0.03px;}
#t1b_4{left:89px;bottom:101px;letter-spacing:-0.04px;word-spacing:0.03px;}
#t1c_4{left:89px;bottom:79px;letter-spacing:-0.13px;word-spacing:-1.09px;}
#t1d_4{left:89px;bottom:56px;letter-spacing:-0.12px;word-spacing:0.1px;}
#t1e_4{left:656px;bottom:755px;letter-spacing:-0.16px;word-spacing:0.13px;}
#t1f_4{left:656px;bottom:733px;letter-spacing:-0.21px;word-spacing:0.19px;}
#t1g_4{left:656px;bottom:710px;letter-spacing:-0.1px;word-spacing:-0.12px;}
#t1h_4{left:656px;bottom:688px;letter-spacing:-0.12px;word-spacing:0.1px;}
#t1i_4{left:656px;bottom:665px;letter-spacing:-0.13px;word-spacing:-0.73px;}
#t1j_4{left:656px;bottom:642px;letter-spacing:-0.12px;word-spacing:0.09px;}
#t1k_4{left:656px;bottom:620px;letter-spacing:-0.19px;word-spacing:0.17px;}
#t1l_4{left:656px;bottom:597px;letter-spacing:-0.14px;word-spacing:0.12px;}
#t1m_4{left:656px;bottom:575px;letter-spacing:-0.16px;word-spacing:-0.81px;}
#t1n_4{left:656px;bottom:552px;letter-spacing:-0.13px;word-spacing:0.11px;}
#t1o_4{left:656px;bottom:514px;letter-spacing:0.07px;word-spacing:-0.11px;}
#t1p_4{left:656px;bottom:485px;letter-spacing:-0.09px;word-spacing:-0.52px;}
#t1q_4{left:656px;bottom:463px;letter-spacing:-0.15px;word-spacing:-0.65px;}
#t1r_4{left:885px;bottom:463px;letter-spacing:-0.05px;word-spacing:-1.17px;}
#t1s_4{left:1093px;bottom:463px;letter-spacing:-0.49px;}
#t1t_4{left:1124px;bottom:463px;letter-spacing:-0.15px;word-spacing:-1.06px;}
#t1u_4{left:656px;bottom:440px;letter-spacing:-0.01px;word-spacing:-0.02px;}
#t1v_4{left:834px;bottom:440px;letter-spacing:-0.1px;word-spacing:0.07px;}
#t1w_4{left:656px;bottom:418px;letter-spacing:-0.06px;word-spacing:0.04px;}
#t1x_4{left:656px;bottom:395px;letter-spacing:-0.12px;word-spacing:0.1px;}
#t1y_4{left:656px;bottom:373px;letter-spacing:-0.06px;word-spacing:0.04px;}
#t1z_4{left:852px;bottom:373px;letter-spacing:-0.01px;word-spacing:-0.02px;}
#t20_4{left:656px;bottom:350px;letter-spacing:-0.04px;}
#t21_4{left:783px;bottom:350px;letter-spacing:-0.11px;word-spacing:0.08px;}
#t22_4{left:656px;bottom:327px;letter-spacing:-0.13px;word-spacing:0.1px;}
#t23_4{left:953px;bottom:335px;letter-spacing:0.45px;}
#t24_4{left:968px;bottom:327px;letter-spacing:-0.09px;word-spacing:0.08px;}
#t25_4{left:656px;bottom:305px;letter-spacing:-0.06px;word-spacing:0.03px;}
#t26_4{left:656px;bottom:282px;letter-spacing:-0.13px;word-spacing:0.11px;}
#t27_4{left:656px;bottom:260px;letter-spacing:-0.04px;word-spacing:0.03px;}
#t28_4{left:957px;bottom:267px;letter-spacing:-0.17px;}
#t29_4{left:656px;bottom:220px;letter-spacing:-0.03px;}
#t2a_4{left:656px;bottom:193px;letter-spacing:-0.11px;word-spacing:-0.67px;}
#t2b_4{left:656px;bottom:170px;letter-spacing:-0.04px;word-spacing:-0.52px;}
#t2c_4{left:656px;bottom:148px;letter-spacing:-0.11px;word-spacing:0.1px;}
#t2d_4{left:656px;bottom:109px;letter-spacing:-0.13px;word-spacing:-0.01px;}
#t2e_4{left:656px;bottom:86px;letter-spacing:-0.07px;word-spacing:-1.15px;}
#t2f_4{left:1163px;bottom:93px;letter-spacing:-1.03px;}
#t2g_4{left:656px;bottom:63px;letter-spacing:-0.13px;word-spacing:0.11px;}
#t2h_4{left:77px;bottom:889px;letter-spacing:0.18px;}

.s0_4{font-size:10px;font-family:ArialMT_5i;color:#000;}
.s1_4{font-size:6px;font-family:ArialMT_5i;color:#000;}
.s2_4{font-size:27px;font-family:Arial-BoldMT_58;color:#000;}
.s3_4{font-size:17px;font-family:Arial-BoldMT_58;color:#000;}
.s4_4{font-size:17px;font-family:ArialMT_5i;color:#000;}
.s5_4{font-size:11px;font-family:ArialMT_5i;color:#000;}
.s6_4{font-size:17px;font-family:ArialMT_5x;color:#000;}
.s7_4{font-size:17px;font-family:ArialMT_5s;color:#000;}
.s8_4{font-size:17px;font-family:Arial-ItalicMT_5n;color:#000;}
.s9_4{font-size:19px;font-family:Arial-BoldMT_58;color:#000;}
.sa_4{font-size:10px;font-family:NimbusSans-Regular_62;color:#000;}
</style>
<!-- End inline CSS -->

<!-- Begin embedded font definitions -->
<style id="fonts4" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_58;
	src: url("fonts/Arial-BoldMT_58.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_5n;
	src: url("fonts/Arial-ItalicMT_5n.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5i;
	src: url("fonts/ArialMT_5i.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5s;
	src: url("fonts/ArialMT_5s.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5x;
	src: url("fonts/ArialMT_5x.woff") format("woff");
}

@font-face {
	font-family: NimbusSans-Regular_62;
	src: url("fonts/NimbusSans-Regular_62.woff") format("woff");
}

</style>
<!-- End embedded font definitions -->

<!-- Begin page background -->
<div id="pg4Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg4" style="-webkit-user-select: none;"><object width="1286" height="909" data="4/4.svg" type="image/svg+xml" id="pdf4" style="width:1286px; height:909px; -moz-transform:scale(1); z-index: 0;"></object></div>
<!-- End page background -->


<!-- Begin text definitions (Positioned/styled in CSS) -->
<div class="text-container"><span id="t1_4" class="t s0_4">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_4" class="t s1_4">© </span>
<span id="t3_4" class="t s0_4">(NCCN </span>
<span id="t4_4" class="t s1_4">© </span>
<span id="t5_4" class="t s0_4">), All rights reserved. NCCN Guidelines </span>
<span id="t6_4" class="t s1_4">® </span>
<span id="t7_4" class="t s0_4">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_4" class="t s2_4">NCCN Guidelines Version 4.2024 </span>
<span id="t9_4" class="t s2_4">Head and Neck Cancers </span>
<span id="ta_4" class="t s3_4">MS-44 </span>
<span id="tb_4" class="t s4_4">complications were also less frequent in the hyperfractionation arm. It </span>
<span id="tc_4" class="t s4_4">should be noted that, in this trial, hyperfractionation was not actually </span>
<span id="td_4" class="t s4_4">compared to standard fractionation, as the control arm of 60 Gy was </span>
<span id="te_4" class="t s4_4">delivered at 2.22 Gy/day, which is considered slightly hypofractionated for </span>
<span id="tf_4" class="t s4_4">NPC. Nonetheless, because tolerability and late complications are a </span>
<span id="tg_4" class="t s4_4">frequent concern associated with reirradiation, hyperfractionation to a </span>
<span id="th_4" class="t s4_4">lower total physical dose has high appeal as an attractive option for </span>
<span id="ti_4" class="t s4_4">patients who are able to manage this rigorous twice-daily schedule. </span>
<span id="tj_4" class="t s4_4">Recommendations regarding NPC reirradiation have been published, </span>
<span id="tk_4" class="t s5_4">567 </span>
<span id="tl_4" class="t s4_4">and reports describe a variety of technical approaches including IMRT, </span>
<span id="tm_4" class="t s4_4">SBRT, and brachytherapy. </span>
<span id="tn_4" class="t s5_4">568-570 </span>
<span id="to_4" class="t s4_4">In general, a fractionated course of IMRT </span>
<span id="tp_4" class="t s4_4">in combination with concurrent chemotherapy is the most frequently used </span>
<span id="tq_4" class="t s4_4">approach when the intent remains curative, with SBRT or more highly </span>
<span id="tr_4" class="t s4_4">hypofractionated schedules (eg, </span><span id="ts_4" class="t s6_4">≥</span><span id="tt_4" class="t s7_4">3 Gy/fraction) being more commonly </span>
<span id="tu_4" class="t s4_4">used in cases of palliative intent. </span>
<span id="tv_4" class="t s3_4">Follow-up/Surveillance </span>
<span id="tw_4" class="t s4_4">Recommendations for surveillance are provided in the algorithm (see </span>
<span id="tx_4" class="t s8_4">Follow-up Recommendations </span><span id="ty_4" class="t s4_4">in the NCCN Guidelines for Head and Neck </span>
<span id="tz_4" class="t s4_4">Cancers). Since the deep areas of the skull base are inaccessible to </span>
<span id="t10_4" class="t s4_4">clinical examination, periodic cross-sectional imaging may be necessary. </span>
<span id="t11_4" class="t s4_4">Likewise, inspection of the nasopharyngeal mucosa may be best </span>
<span id="t12_4" class="t s4_4">accomplished with periodic endoscopy. The clinical benefit of plasma EBV </span>
<span id="t13_4" class="t s4_4">DNA monitoring is not yet clearly defined (see </span><span id="t14_4" class="t s8_4">Epstein-Barr Virus</span><span id="t15_4" class="t s4_4">, </span><span id="t16_4" class="t s4_4">above), </span>
<span id="t17_4" class="t s4_4">but it may be considered in centers with experience (category 2B). </span>
<span id="t18_4" class="t s9_4">Cancer of the Larynx </span>
<span id="t19_4" class="t s4_4">The larynx is divided into three regions: supraglottis, glottis, and subglottis. </span>
<span id="t1a_4" class="t s4_4">The distribution of cancers is as follows: 30% to 35% in the supraglottic </span>
<span id="t1b_4" class="t s4_4">region, 60% to 65% in the glottic region, and 5% in the subglottic region. </span>
<span id="t1c_4" class="t s4_4">The incidence and pattern of metastatic spread to regional nodes vary with </span>
<span id="t1d_4" class="t s4_4">the primary region. The lymphatic drainage of the glottis is sparse and </span>
<span id="t1e_4" class="t s4_4">early-stage primaries rarely spread to regional nodes. Because </span>
<span id="t1f_4" class="t s4_4">hoarseness is an early symptom, most glottic cancers are early stage at </span>
<span id="t1g_4" class="t s4_4">diagnosis. Thus, glottic cancer has an excellent cure rate of 80% to 90%. </span>
<span id="t1h_4" class="t s4_4">Nodal involvement adversely affects survival rates and is rare in T1–2 </span>
<span id="t1i_4" class="t s4_4">disease. In contrast, more than 50% of patients with supraglottic primaries </span>
<span id="t1j_4" class="t s4_4">present with spread to regional nodes because of an abundant lymphatic </span>
<span id="t1k_4" class="t s4_4">network that crosses the midline. Bilateral cervical metastases are not </span>
<span id="t1l_4" class="t s4_4">uncommon with early-stage supraglottic primaries. Thus, supraglottic </span>
<span id="t1m_4" class="t s4_4">cancer is often metastatic and higher stage at diagnosis. Subglottic cancer </span>
<span id="t1n_4" class="t s4_4">is not discussed, because it is uncommon. </span>
<span id="t1o_4" class="t s3_4">Workup and Staging </span>
<span id="t1p_4" class="t s4_4">The evaluation of the patient to determine tumor stage is similar for glottic </span>
<span id="t1q_4" class="t s4_4">and supraglottic primaries (see </span><span id="t1r_4" class="t s8_4">Cancer of the Glottic Larynx </span><span id="t1s_4" class="t s4_4">and </span><span id="t1t_4" class="t s8_4">Cancer of </span>
<span id="t1u_4" class="t s8_4">the Supraglottic Larynx </span><span id="t1v_4" class="t s4_4">in the NCCN Guidelines for Head and Neck </span>
<span id="t1w_4" class="t s4_4">Cancers). Multidisciplinary consultation is frequently indicated for both </span>
<span id="t1x_4" class="t s4_4">sites because of the potential impact on voice quality, speech, and </span>
<span id="t1y_4" class="t s4_4">swallowing functions (see </span><span id="t1z_4" class="t s8_4">Principles of Nutrition: Management and </span>
<span id="t20_4" class="t s8_4">Supportive Care </span><span id="t21_4" class="t s4_4">in the NCCN Guidelines for Head and Neck Cancers). </span>
<span id="t22_4" class="t s4_4">The 2017 AJCC staging classification (8 </span>
<span id="t23_4" class="t s5_4">th </span>
<span id="t24_4" class="t s4_4">edition) for laryngeal primary </span>
<span id="t25_4" class="t s4_4">tumors is determined by the number of subsites involved, vocal cord </span>
<span id="t26_4" class="t s4_4">mobility, the presence of metastases, extranodal extension, and invasion </span>
<span id="t27_4" class="t s4_4">of thyroid/cricoid cartilage (see Table 5). </span>
<span id="t28_4" class="t s5_4">391 </span>
<span id="t29_4" class="t s3_4">Treatment </span>
<span id="t2a_4" class="t s4_4">In the NCCN Guidelines, the treatment of patients with laryngeal cancer is </span>
<span id="t2b_4" class="t s4_4">divided into two categories: 1) tumors of the glottic larynx; or 2) tumors of </span>
<span id="t2c_4" class="t s4_4">the supraglottic larynx. </span>
<span id="t2d_4" class="t s4_4">For patients with carcinoma in situ of the larynx, recommended treatment </span>
<span id="t2e_4" class="t s4_4">options include: 1) endoscopic resection, which is preferred; or 2) RT. </span>
<span id="t2f_4" class="t s5_4">571,572 </span>
<span id="t2g_4" class="t s4_4">For early-stage glottic or supraglottic cancer, a systematic review </span>
<span id="t2h_4" class="t sa_4">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>
<!-- End text definitions -->


</div>
</body>
</html>
